HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION

HCV-HIV 混合感染：免疫功能障碍的影响

• 批准号: 8166531
• 负责人: RICHARD K. STERLING
• 金额: $ 8.44万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166531
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; HIV; Hepatitis C virus; Histologic; Immune System Diseases; Immunocompetence; Individual; Institution; Liver Fibrosis; Natural History; Patients; Reporting; Research; Research Personnel; Resources; Severities; Source; United States National Institutes of Health; Virus Diseases; anti-hepatitis C; effective therapy; improved; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Effective therapy for human immunodeficiency virus (HIV) infection has markedly prolonged survival in infected individuals. As a result, other comorbid conditions in these patients are becoming more clinically important. Approximately 30% of HIV infected patients are also infected with hepatitis C virus (HCV) which is now the leading co-morbid disease in HIV-infected individuals. The histologic severity and natural history of HCV is reported to be accelerated in those co-infected with HIV. Although treatment of HCV has improved, the response rates in co-infected individuals remains suboptimal. It is hypothesized that: 1) the severity and progression of hepatic fibrosis in patients with HIV-HCV coinfection is directly related to the immunologic competence of the individual, and 2) the virologic response to anti-HCV treatment is directly related to the degree of immunologic competence.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 针对人类免疫缺陷病毒（HIV）感染的有效治疗可显着延长感染者的生存期。 因此，这些患者的其他合并症在临床上变得越来越重要。 大约 30% 的 HIV 感染患者还感染丙型肝炎病毒 (HCV)，丙型肝炎病毒目前是 HIV 感染者的主要合并症。 据报道，在同时感染 HIV 的患者中，HCV 的组织学严重程度和自然病程会加速。尽管丙型肝炎病毒的治疗有所改善，但合并感染者的缓解率仍然不理想。 假设：1) HIV-HCV 合并感染患者肝纤维化的严重程度和进展与个体的免疫能力直接相关，2) 抗 HCV 治疗的病毒学反应与肝纤维化程度直接相关。免疫能力。